The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.
AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...
HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...
Emirates News Agency on MSN3d
US pharmaceutical giant opens R&D center in BeijingBEIJING - US pharmaceutical giant Pfizer's new research and development (R&D) center officially opened at BioPark in the ...
The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...
As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...
Beijing: AstraZeneca has announced an investment of USD 2.5 billion in Beijing to establish its sixth global strategic R&D ...
The forum came as Beijing seeks to attract foreign investment as its economy grappled with sluggish domestic consumption and ...
The pharmaceutical firm expects its workforce in Beijing to grow to 1,700 employees and is launching a JV with BioKangtai to ...
Since 2023, AstraZeneca has invested more than USD1.7 billion to expand its production in China, including spending USD750 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback